Key result
Bolus IV injection of E6010 reduced premature ventricular complexes and tended to lower mortality compared to native t-PA or urokinase in dogs.
Why the study?
Does bolus intravenous injection of E6010 reduce reperfusion arrhythmias and mortality compared to continuous intravenous native t-PA or urokinase in dogs with coronary thrombi?
Does bolus intravenous injection of E6010 reduce reperfusion arrhythmias and mortality compared to continuous intravenous native t-PA or urokinase in dogs with coronary thrombi?
Bolus intravenous injection of the novel modified t-PA E6010 reduced reperfusion arrhythmias and showed a trend toward lower mortality compared to continuous intravenous native t-PA or urokinase in a canine model of coronary thrombolysis.
Answers are grounded in this paper and cite their sources.
Supports bolus E6010 for arrhythmia reduction in dogs; leaves open translation to clinical thrombolysis.
The aim of this study was to compare the effects of a novel modified tissue-type plasminogen activator (t-PA), E6010, to those of native t-PA and urokinase on reperfusion arrhythmias (premature ventricular complexes: PVC) and the mortality rate after coronary thrombolysis. The frequency of PVC and the mortality rate were evaluated in anesthetized dogs which had 1-, 3- or 6-h-old thrombi induced by a copper coil in the coronary artery. Thrombolytic treatment with a bolus intravenous (iv) injection of E6010 was compared with the continuous iv administration of native t-PA or urokinase. The frequency of PVC was significantly lower in the E6010 group than in the native t-PA and urokinase groups (P < 0.05). The mortality rate in the E6010 group (0.0%) tended to be lower than those in the native t-PA group (10.7%) and the urokinase group (7.1%). These results indicate that the bolus iv injection of E6010 reduced both PVC and the mortality rate, compared with the continuous iv administration of native t-PA or urokinase for coronary thrombolysis; Therefore, E6010 may have beneficial effects in prehospital thrombolysis.
No takes yet. Share an insight, caveat, or question.
Saitō et al. (1995) studied Coronary thrombolysis and reperfusion arrhythmias. E6010 (novel modified t-PA) vs. Continuous intravenous administration of native t-PA or urokinase was evaluated on Frequency of premature ventricular complexes (PVC) and mortality rate (p=< 0.05). Bolus IV injection of E6010 reduced premature ventricular complexes and tended to lower mortality compared to native t-PA or urokinase in dogs.
Synapse has enriched 10 related papers. Consider them for comparative context: